NIFTY PHARMA PE Ratio — Live & 20-Year Historical Valuation
The NIFTY PHARMA PE ratio is 37.06 as of 5 Jun 2026, with a PB ratio of 5.18 and a dividend yield of 0.75%. On long-term valuations this is currently Highly Overvalued. The interactive heatmap below shows monthly PE, PB and dividend-yield for NIFTY PHARMA going back over two decades (2005–2026).
Valuation verdict
Above its long-term average
62th percentile vs its history · median PE 34.2
Earnings yield (1 ÷ PE)
2.70%
What the index "earns" relative to price
Current PE
37.06
vs all-time median 34.2
| Period | Low PE | Current | High PE |
|---|---|---|---|
| 1 Month | 37.1 | 37.1 | 37.1 |
| 3 Months | 34.8 | 37.1 | 37.6 |
| 6 Months | 33.1 | 37.1 | 37.6 |
| 1 Year | 31.6 | 37.1 | 37.6 |
| 3 Years | 29.9 | 37.1 | 39.3 |
| 5 Years | 27.9 | 37.1 | 39.3 |
| Max | 17.3 | 37.1 | 77.0 |
Index PENIFTY PHARMA
PE (TTM)37.06
PB Ratio5.18
Div Yield0.75%
Zone
Highly Overvalued
H: 77.0L: 17.3Avg: 36.2Med: 34.2
PE Ratio — Monthly Heatmap
Low
High
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 33.1 | 34.4 | 33.3 | 34.8 | 37.6 | 37.1 | — | — | — | — | — | — |
| 2025 | 33.3 | 29.9 | 32.0 | 32.8 | 30.7 | 31.6 | 32.3 | 31.6 | 33.1 | 33.9 | 34.0 | 33.6 |
| 2024 | 36.0 | 36.3 | 36.6 | 36.6 | 34.1 | 35.8 | 39.3 | 38.8 | 38.8 | 37.3 | 35.1 | 37.0 |
| 2023 | 31.0 | 30.9 | 31.6 | 33.1 | 27.9 | 30.1 | 32.3 | 31.9 | 32.5 | 30.4 | 32.7 | 33.9 |
| 2022 | 31.0 | 31.4 | 33.0 | 32.7 | 33.4 | 36.8 | 38.7 | 37.4 | 36.5 | 37.1 | 34.2 | 32.7 |
| 2021 | 36.3 | 33.2 | 32.3 | 35.5 | 35.9 | 36.4 | 37.4 | 30.5 | 31.0 | 29.7 | 32.0 | 33.3 |
| 2020 | 25.8 | 23.4 | 22.2 | 28.8 | 30.1 | 30.5 | 32.9 | 31.7 | 33.7 | 34.8 | 35.2 | 38.4 |
| 2019 | 48.3 | 49.9 | 52.7 | 53.0 | 40.8 | 38.4 | 34.4 | 32.9 | 29.5 | 30.8 | 25.6 | 25.8 |
| 2018 | 47.4 | 46.9 | 45.4 | 50.9 | 46.6 | 52.2 | 53.2 | 51.4 | 49.4 | 47.4 | 51.0 | 48.8 |
| 2017 | 38.2 | 38.0 | 37.4 | 36.4 | 33.5 | 35.5 | 35.0 | 43.4 | 45.1 | 47.9 | 45.2 | 47.2 |
| 2016 | 59.5 | 42.2 | 41.5 | 42.7 | 42.5 | 43.0 | 45.2 | 44.1 | 43.0 | 44.6 | 39.6 | 38.1 |
| 2015 | 40.1 | 48.6 | 52.9 | 51.9 | 56.3 | 54.2 | 55.4 | 77.0 | 75.3 | 73.5 | 58.2 | 60.6 |
| 2014 | 50.0 | 48.8 | 45.0 | 48.3 | 38.4 | 42.5 | 41.6 | 31.3 | 33.7 | 36.2 | 36.2 | 35.2 |
| 2013 | 43.3 | 31.4 | 32.4 | 35.6 | 39.5 | 42.5 | 46.5 | 43.5 | 45.9 | 46.3 | 47.5 | 49.2 |
| 2012 | 30.9 | 46.8 | 48.9 | 50.1 | 42.5 | 41.8 | 44.3 | 54.0 | 53.2 | 48.2 | 43.5 | 44.7 |
| 2011 | 25.9 | 25.2 | 26.4 | 26.9 | 30.2 | 30.1 | 29.0 | 26.4 | 26.4 | 28.3 | 29.1 | 28.3 |
| 2010 | 34.0 | 26.8 | 29.1 | 28.9 | 23.0 | 24.1 | 23.1 | 24.1 | 26.3 | 28.3 | 28.4 | 29.1 |
| 2009 | 24.4 | 24.0 | 25.9 | 36.9 | 40.2 | 38.8 | 33.6 | 35.4 | 40.5 | 33.5 | 37.4 | 39.4 |
| 2008 | 22.1 | 24.3 | 24.2 | 26.6 | 27.7 | 26.2 | 26.8 | 28.0 | 23.4 | 17.3 | 20.4 | 20.9 |
| 2007 | 25.7 | 23.5 | 25.1 | 24.3 | 23.2 | 22.5 | 20.3 | 19.8 | 21.1 | 22.6 | 22.2 | 25.2 |
| 2006 | 34.4 | 37.9 | 41.3 | 34.5 | 31.6 | 29.5 | 29.2 | 32.2 | 33.3 | 28.8 | 29.6 | 30.3 |
| 2005 | — | — | — | — | — | — | 30.9 | 34.8 | 33.7 | 29.2 | 32.5 | 33.4 |
Undervalued
PE < 15
Fair Value
PE 15–20
Overvalued
PE 20–25
Expensive
PE > 25